This is a review about HER2, based on 105 published articles (read how Labome selects the articles), using HER2 antibody in all methods. It is aimed to help Labome visitors find the most suited HER2 antibody.
HER2 synonym: CD340; HER-2; HER-2/neu; HER2; MLN 19; NEU; NGL; TKR1; c-erb B2/neu protein; herstatin; human epidermal growth factor receptor 2; metastatic lymph node gene 19 protein; neuro/glioblastoma derived oncogene homolog; neuroblastoma/glioblastoma derived oncogene homolog; p185erbB2; proto-oncogene Neu; proto-oncogene c-ErbB-2; tyrosine kinase-type cell surface receptor HER2; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; v-erb-b2 avian erythroblastic leukemia viral oncoprotein 2; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog

Invitrogen
rabbit monoclonal (EP1045Y)
  • IHC; human; ready to use
In order to evaluate the expression of CD24, CD44, CD133 and ALDH1 in invasive ductal carcinoma of the breast, Invitrogen HER2 antibody (Thermo Scientific, RM-2111-R7) was used in immunohistochemistry on human samples at ready to use. Pathol Res Pract (2015) ncbi
rabbit monoclonal (SP3)
  • IHC; human; ready to use
In order to evaluate the expression of CD24, CD44, CD133 and ALDH1 in invasive ductal carcinoma of the breast, Invitrogen HER2 antibody (Thermo Scientific, RM-9103-R7) was used in immunohistochemistry on human samples at ready to use. Pathol Res Pract (2015) ncbi
rabbit monoclonal (SP3)
  • IHC-P; human; 1:200
In order to assess the clinicopathological and immunohistochemical characteristics, and the clinical outcomes, between screen-detected and symptomatic DCIS, Invitrogen HER2 antibody (Thermo Scientific Lab Vision, RM-9103-S) was used in immunohistochemistry - paraffin section on human samples at 1:200. Breast Cancer Res Treat (2015) ncbi
mouse monoclonal (e2-4001 + 3B5)
  • IP; human; 1 ug/time
In order to characterize nine mutations in the receptor tyrosine kinase ERBB4 identified in lung adenocarcinoma, Invitrogen HER2 antibody (Thermo Scientific, MA5-14057) was used in immunoprecipitation on human samples at 1 ug/time. Oncogene (2016) ncbi
rabbit monoclonal (SP3)
  • IHC; human; 1:100
Invitrogen HER2 antibody (Thermo Scientific, SP3) was used in immunohistochemistry on human samples at 1:100. Breast (2015) ncbi
mouse monoclonal (e2-4001)
  • IHC; human; 1:200
In order to evaluate expression of receptor tyrosine kinases, their ligands, and mutational status and correlate with features observed in solitary fibrous tumors, Invitrogen HER2 antibody (Lab vision, MS-325-PO) was used in immunohistochemistry on human samples at 1:200. Hum Pathol (2015) ncbi
rabbit monoclonal (SP3)
  • IHC-P; human
In order to discuss how to treat the four types of breast cancer, Invitrogen HER2 antibody (Thermo Scientific Lab Vision, SP3) was used in immunohistochemistry - paraffin section on human samples. Niger J Clin Pract (2015) ncbi
mouse monoclonal (e2-4001 + 3B5)
  • IHC-P; human; 1:500
Invitrogen HER2 antibody (Thermo Scientific, e2-4001-3B5) was used in immunohistochemistry - paraffin section on human samples at 1:500. Turk J Gastroenterol (2014) ncbi
mouse monoclonal (e2-4001 + 3B5)
  • IHC-P; human; 1:100
Invitrogen HER2 antibody (Lab Vision, e2-4001+ 3B5) was used in immunohistochemistry - paraffin section on human samples at 1:100. World J Urol (2015) ncbi
mouse monoclonal (e2-4001)
  • IHC; human
In order to determine the best method to assess HER2 status in breast cancer samples, Invitrogen HER2 antibody (LabVision, Ab8) was used in immunohistochemistry on human samples. Breast Cancer Res (2015) ncbi
mouse monoclonal (3B5)
  • IHC; human
In order to determine the best method to assess HER2 status in breast cancer samples, Invitrogen HER2 antibody (LabVision, Ab15) was used in immunohistochemistry on human samples. Breast Cancer Res (2015) ncbi
mouse monoclonal (e2-4001 + 3B5)
  • IHC-P; human
In order to determine the rate of human epidermal growth factor receptor-2 discordance and its effect on treatment decisions in patients with advanced gastric cancer, Invitrogen HER2 antibody (Thermo, e2 4001+3B5) was used in immunohistochemistry - paraffin section on human samples. Jpn J Clin Oncol (2015) ncbi
rabbit monoclonal (SP3)
  • IHC; human; 1:200
In order to evaluate the presence of cancer stem cells and EMT markers as prognostic markers for breast metaplastic carcinoma, Invitrogen HER2 antibody (Neomarker, RM-9103-R7) was used in immunohistochemistry on human samples at 1:200. Breast Cancer Res Treat (2015) ncbi
mouse monoclonal (CB11)
  • WB; human
In order to evaluate the role of leptin/STAT3 and HER2 receptor in tamoxifen resistance, Invitrogen HER2 antibody (Thermo Fisher Scientific, MS-441-S) was used in western blot on human samples. Cell Oncol (Dordr) (2015) ncbi
mouse monoclonal (CB11)
  • IHC; human; 1:600
In order to evaluate the prevalence, characteristics, prognosis, and effective treatment modalities in patients with primary squamous cell carcinoma of the breast, Invitrogen HER2 antibody (Zymed, CB11) was used in immunohistochemistry on human samples at 1:600. Breast Cancer Res Treat (2015) ncbi
rabbit monoclonal (SP3)
  • IHC-P; human
Invitrogen HER2 antibody (Lab Vision Corporation, SP3) was used in immunohistochemistry - paraffin section on human samples. Exp Ther Med (2015) ncbi
rabbit monoclonal (SP3)
  • IHC; human; 1:100
Invitrogen HER2 antibody (Thermo Scientific, SP3) was used in immunohistochemistry on human samples at 1:100. BMC Womens Health (2014) ncbi
mouse monoclonal (9G6.10)
  • WB; human
Invitrogen HER2 antibody (Thermo Scientific, 9G6.10) was used in western blot on human samples. J Biol Chem (2014) ncbi
mouse monoclonal (e2-4001)
  • WB; human
  • IP; human
In order to study mechanism of resistance to the FGFR inhibitor BGJ398 and the FGFR inhibitor ponatinib, Invitrogen HER2 antibody (NeoMarkers, e2-4001) was used in western blot on human samples and in immunoprecipitation on human samples. Oncogene (2015) ncbi
mouse monoclonal (TAB250)
  • IC; human; 1:200
  • IHC; human; 1:200
In order to investigate the role of CEACAM6 in luminal, HER2-enriched, and basal-like breast cancers, Invitrogen HER2 antibody (Zymed, TAB250) was used in immunocytochemistry on human samples at 1:200 and in immunohistochemistry on human samples at 1:200. Am J Pathol (2014) ncbi
mouse monoclonal (e2-4001)
  • IHC-P; human; 1:300
Invitrogen HER2 antibody (LabVision, e2-4001) was used in immunohistochemistry - paraffin section on human samples at 1:300. Head Neck (2015) ncbi
mouse monoclonal (e2-4001 + 3B5)
  • IHC-P; human
In order to investigate the expression and activity of receptor tyrosine kinases, MAP kinase, AKT, or Hippo pathways in human schwannomas, Invitrogen HER2 antibody (LabVision, Ab-17) was used in immunohistochemistry - paraffin section on human samples. Neuro Oncol (2014) ncbi
mouse monoclonal (2G11)
  • FC; human; fig 2
In order to evaluate the expression of the c-erbB-2 gene and c-erbB-2 antigen in breast cancer cells type BT-474, MCF-7 and MDA-MB-231 as targets for magnetic nanoparticles, Invitrogen HER2 antibody (Invitrogen, AHO0918) was used in flow cytometry on human samples (fig 2). Conf Proc IEEE Eng Med Biol Soc (2013) ncbi
mouse monoclonal (CB11)
  • IHC-P; human; 1:100; fig 1
In order to study BRAC1-deficiency in sporadic breast cancer, Invitrogen HER2 antibody (Life Technologies, CB11) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 1). Tumour Biol (2013) ncbi
mouse monoclonal (CB11)
  • IHC-P; human; 1:600; fig 2
In order to study triple negative breast cancer in Chinese women, Invitrogen HER2 antibody (Zymed, clone CB11) was used in immunohistochemistry - paraffin section on human samples at 1:600 (fig 2). Int J Clin Exp Pathol (2013) ncbi
mouse monoclonal (e2-4001)
  • IC; human; fig 3
  • WB; human; fig 1
In order to investigate factors that regulate ErbB2-ErbB3 heterodimerization, Invitrogen HER2 antibody (Thermo, Ab-8 (clone e2-4001)) was used in immunocytochemistry on human samples (fig 3) and in western blot on human samples (fig 1). Carcinogenesis (2013) ncbi
rabbit polyclonal (Z4881)
  • WB; human; fig 2
In order to investigate factors that regulate ErbB2-ErbB3 heterodimerization, Invitrogen HER2 antibody (Life Technologies, Z4881) was used in western blot on human samples (fig 2). Carcinogenesis (2013) ncbi
mouse monoclonal (CB11)
  • IHC; human; fig 3
In order to report the case of primary acinic cell carcinoma of the breast in a 38-year-old woman, Invitrogen HER2 antibody (Zymed, CB11) was used in immunohistochemistry on human samples (fig 3). Int J Surg Pathol (2014) ncbi
mouse monoclonal (CB11)
  • IHC-P; human; fig 2
In order to investigate prognostic or predictive biomarkers of breast cancer, Invitrogen HER2 antibody (Life Technologies, Clone CB11) was used in immunohistochemistry - paraffin section on human samples (fig 2). PLoS ONE (2013) ncbi
mouse monoclonal (e2-4001)
  • FC; human; fig 5
In order to study the influence of oncogene expression on cellular lipid profile, Invitrogen HER2 antibody (Biosource, AHO1011) was used in flow cytometry on human samples (fig 5). Biochim Biophys Acta (2012) ncbi
not indicated
  • WB; human
Biosource anti-ErbB-2 antibody was used for western blot in order to investigate the role of Prdx1 in the regulation of tumorigenesis.EMBO J (2009) ncbi
not indicated
  • IHC; human
Zymed monoclonal mouse anti-human Her-2 antibody (clone TAB250) was used in immunohistochemistry to demonstrate whether overexpression of EMP3 in primary breast carcinoma is not associated with DNA methylationJ Korean Med Sci (2009) ncbi
not indicated
  • WB; human
Neomarkers mouse anti-ERBB2 antibody (catalog no:Ab-17) was used in western blot to combine computational simulations, experimental testing of simulation results, and finally reverse engineering of a protein interaction network to define potential therapeutic strategies for de novo trastuzumab resistant breast cancerBMC Syst Biol (2009) ncbi
not indicated
  • WB; human
Invitrogen anti-total HER2 and anti-phospho-HER2 (Y1248) antibodies were used in western blot to investigate potential links between decreased BRCA1 levels and responses to Tam in ER-positive human breast cancer cell lines (T47D and ZR-75-1).Oncogene (2009) ncbi
not indicated
  • IHC; human
Zymed Laboratories anti-c-erbB-2 antibody was used in immunohistochemistry to investigate the relationship between amphiregulin expression and liver metastases of colorectal cancer.Clin Cancer Res (2008) ncbi
mouse monoclonal (CB11)
  • IHC-P; human; 1:3
In order to discuss features used to classify pure mucinous carcinomas of the breast, Invitrogen HER2 antibody (Zymed, CB11) was used in immunohistochemistry - paraffin section on human samples at 1:3. Cancer (2002) ncbi
mouse monoclonal (TAB250)
  • IHC; human; 1:20
In order to describe a patient affected by endometrial cancer and treated primarily with leuprolide, Invitrogen HER2 antibody (Zymed, TAB 250) was used in immunohistochemistry on human samples at 1:20. Br J Cancer (2001) ncbi
Santa Cruz Biotechnology
rabbit polyclonal (C-18)
  • WB; mouse; 1:500
Santa Cruz Biotechnology HER2 antibody (Santa Cruz, sc-284) was used in western blot on mouse samples at 1:500. Mol Oncol (2015) ncbi
rabbit polyclonal (C-18)
  • WB; rat; fig 2
Santa Cruz Biotechnology HER2 antibody (Santa Cruz, sc-284) was used in western blot on rat samples (fig 2). J Biol Chem (2015) ncbi
rabbit polyclonal (C-18)
  • WB; rat
In order to study the role of Neuregulin1/ErbB system during peripheral nerve degeneration and regeneration, Santa Cruz Biotechnology HER2 antibody (Santa Cruz, sc-284) was used in western blot on rat samples. Eur J Neurosci (2016) ncbi
rabbit polyclonal (C-18)
  • WB; mouse
Santa Cruz Biotechnology HER2 antibody (Santa Cruz Biotechnology, sc-284) was used in western blot on mouse samples. Am J Physiol Gastrointest Liver Physiol (2015) ncbi
rabbit polyclonal (C-18)
  • WB; human
  • WB; mouse
Santa Cruz Biotechnology HER2 antibody (Santa Cruz, sc-284) was used in western blot on human samples and on mouse samples. Mol Cell Biol (2014) ncbi
rabbit polyclonal (C-18)
  • IHC; mouse; 1:250
Santa Cruz Biotechnology HER2 antibody (Santa Cruz Biotechnology, sc-284) was used in immunohistochemistry on mouse samples at 1:250. Oncotarget (2014) ncbi
mouse monoclonal (3B5)
  • WB; human
Santa Cruz Biotechnology HER2 antibody (Santa Cruz Biotechnology, sc-33684) was used in western blot on human samples. Int J Oncol (2014) ncbi
rabbit polyclonal (Tyr 1248)
  • WB; human
Santa Cruz Biotechnology HER2 antibody (Santa Cruz, sc-12352-R) was used in western blot on human samples. J Biol Chem (2014) ncbi
rabbit polyclonal (C-18)
  • WB; human
Santa Cruz Biotechnology HER2 antibody (Santa Cruz, sc-284) was used in western blot on human samples. J Biol Chem (2014) ncbi
rabbit polyclonal (C-18)
  • IHC; mouse; 1:400
Santa Cruz Biotechnology HER2 antibody (Santa Cruz Biotechnology, sc-284) was used in immunohistochemistry on mouse samples at 1:400. Endocr Relat Cancer (2014) ncbi
mouse monoclonal (9G6)
  • IHC-P; human; 1:100
Santa Cruz Biotechnology HER2 antibody (Santa Cruz, sc-08) was used in immunohistochemistry - paraffin section on human samples at 1:100. J Biol Chem (2014) ncbi
rabbit polyclonal (C-18)
  • IP; mouse
  • WB; mouse
Santa Cruz Biotechnology HER2 antibody (Santa Cruz, SC-284) was used in immunoprecipitation on mouse samples and in western blot on mouse samples. PLoS ONE (2013) ncbi
rabbit polyclonal (C-18)
  • WB; human
Santa Cruz Biotechnology HER2 antibody (Santa Cruz, sc-284) was used in western blot on human samples. J Biol Chem (2013) ncbi
not indicated
  • WB; human
  • IC; human
  • IP; human
Santa Cruz Biotechnology ErbB-2 (C-18) and ErbB-2 (9G6) antibodes were used to carry out western blot, immunoprecipitation, and immunofluorescence staining analysis in order to investigate the signal cross talk between ErbB2 and PR receptor and the effect on breast cancer growth.Mol Cell Biol (2009) ncbi
not indicated
  • WB; human
Santa Cruz anti-total HER2 and anti-phospho-HER2 (Y1248) antibodies were used in western blot to investigate potential links between decreased BRCA1 levels and responses to Tam in ER-positive human breast cancer cell lines (T47D and ZR-75-1).Oncogene (2009) ncbi
not indicated
  • WB; human
Santa Cruz Biotechnology ERBB2 antibody was used in western blot in order to show that Hsp90 co-chaperone CDC37 can maintain the oncogenic protein kinase clients.Oncogene (2009) ncbi
not indicated
  • WB; human
Santa Cruz Neu atibody was used in western blot to study the role of DecR1 in mammary tumor development.Mol Cell Biol (2007) ncbi
rabbit polyclonal (C-18)
  • WB; mouse; fig 4
Santa Cruz Biotechnology HER2 antibody (Santa Cruz, sc-284) was used in western blot on mouse samples (fig 4). Oncogene (2005) ncbi
EMD Millipore
rabbit polyclonal
  • WB; human
EMD Millipore HER2 antibody (Millipore, 06562) was used in western blot on human samples. Br J Cancer (2015) ncbi
rabbit polyclonal
  • IHC-P; human; 1:400
In order to investigate global expression changes during metastatic disease progression, EMD Millipore HER2 antibody (Merck Millipore, 06-229) was used in immunohistochemistry - paraffin section on human samples at 1:400. Clin Cancer Res (2015) ncbi
mouse monoclonal (N3/D10)
  • IC; human; 1:1000; fig 4
In order to describe the proxHCR method for the detection of protein interactions and posttranslational modifications in microscopy and flow cytometry, EMD Millipore HER2 antibody (Millipore, 05-1130) was used in immunocytochemistry on human samples at 1:1000 (fig 4). Nat Commun (2015) ncbi
rabbit polyclonal
  • WB; human
EMD Millipore HER2 antibody (Millipore, 06-229) was used in western blot on human samples. J Biol Chem (2014) ncbi
rabbit polyclonal
  • WB; human
EMD Millipore HER2 antibody (Millipore, 06-562) was used in western blot on human samples. J Biol Chem (2014) ncbi
not indicatedCalbiochem ErbB2 inhibitor AG825 was used to treat cells at 5- M concentration in order to demonstrate a functional cross-talk between AR and ErbB2 pathwaysNeoplasia (2008) ncbi
not indicated
  • WB; human
Calbiochem anti-Her2 Ab3 antibody was used in western blot and immunoprecipitation to identify LRIG1 as a novel negative regulator of the Met receptor and its role on opposing Met and Her2 synergyMol Cell Biol (2007) ncbi
not indicated
  • WB; human
Calbiochem ErbB2 antibody was used in western blot to study the expression and role of Nrdp1 in cancer.Cancer Res (2006) ncbi
not indicated
  • IHC; human
Chemicon mouse monoclonal anti-NeuN antibody (1:200) was used in immunohistochemistry to compare GDNF, BDNF, or both, for their capabilities to correct behavioral deficits and protect nigrostriatal dopaminergic neurons in a rat model of PD..Brain Res (2005) ncbi
not indicated
  • WB; human
Upstate Biotechnology polyclonal HER-2 and phospho-HER-2 antibodies were used in western blot to study the inhibition EGFR family members in colon and breast cancer cellsMol Cancer Ther (2005) ncbi
not indicated
  • IP; human
Oncogene Research HER-2 mAb (Ab-3) was used in western blot and immunoprecipitation to study HER-2 down-regulation in colon cancer cellsJ Biol Chem (2005) ncbi
not indicated
  • WB; human
Oncogene Research Products HER2 antibody was used in western blot to study gene regulation by anti-HER2 antibodyJ Biol Chem (2005) ncbi
BioLegend
mouse monoclonal (24D2)
  • FC; human
In order to describe a novel, non-invasive, and adaptable method for the capture and genetic analysis of single tumor cells from cancer patients, BioLegend HER2 antibody (BioLegend, 324406) was used in flow cytometry on human samples. Front Oncol (2014) ncbi
Epitomics
rabbit monoclonal
  • WB; human
In order to determine how HER2/HER3 regulates extracellular acidification and cell migration, Epitomics HER2 antibody (Epitomics, 2064-1) was used in western blot on human samples. Cell Signal (2014) ncbi
WILEX Inc.
not indicated
  • IHC; human
Oncogene anti-c-erbB-2 antibody (clone BP53.12) was used in immunohistochemistry to investigate the expressions of EGFR and pEGFR and their correlation with overall and disease-free survival, clinicopathological parameters and biological markers of invasion and angiogenesis.Breast Cancer Res (2008) ncbi
Cell Signaling Technology
rabbit polyclonal
  • WB; human
Cell Signaling Technology HER2 antibody (Cell Signaling, 2247) was used in western blot on human samples. Br J Cancer (2015) ncbi
rabbit monoclonal (6B12)
  • WB; human; fig 4
Cell Signaling Technology HER2 antibody (Cell Signaling, 2243) was used in western blot on human samples (fig 4). EBioMedicine (2015) ncbi
rabbit monoclonal (29D8)
  • IHC-P; human; 1:25
In order to develop and characterize patient-derived primary xenografts to a model of muscle invasive bladder cancer, Cell Signaling Technology HER2 antibody (Cell Signaling, 2165) was used in immunohistochemistry - paraffin section on human samples at 1:25. Oncotarget (2015) ncbi
rabbit monoclonal (29D8)
  • WB; human; 1:100
In order to study the role of Tn expression and post-translationally modifications in pancreatic ductal adenocarcinoma, Cell Signaling Technology HER2 antibody (Cell Signaling, #2165) was used in western blot on human samples at 1:100. Mol Cancer (2015) ncbi
rabbit polyclonal
  • WB; human; 1:500
Cell Signaling Technology HER2 antibody (Cell Signaling, 2242S) was used in western blot on human samples at 1:500. Breast Cancer Res Treat (2015) ncbi
rabbit monoclonal (29D8)
  • WB; human
Cell Signaling Technology HER2 antibody (Cell Signaling Technology, 2165) was used in western blot on human samples. J Diabetes (2015) ncbi
rabbit monoclonal (29D8)
  • WB; human
In order to identify mechanisms by which metastatic gastroesophageal adenocarcinomas develop resistance to ERBB2 inhibition, Cell Signaling Technology HER2 antibody (Cell Signaling Technologies, 2165) was used in western blot on human samples. PLoS ONE (2014) ncbi
rabbit monoclonal (D8F12)
  • WB; human
Cell Signaling Technology HER2 antibody (Cell Signaling Technology, 4290) was used in western blot on human samples. Cancer Res (2014) ncbi
rabbit monoclonal (D66B7)
  • WB; human
Cell Signaling Technology HER2 antibody (Cell Signaling Technology, 6942) was used in western blot on human samples. Cancer Res (2014) ncbi
rabbit monoclonal (6B12)
  • WB; human
In order to study mechanism of resistance to the FGFR inhibitor BGJ398 and the FGFR inhibitor ponatinib, Cell Signaling Technology HER2 antibody (cell signaling, 2243S) was used in western blot on human samples. Oncogene (2015) ncbi
mouse monoclonal (44E7)
  • WB; human; 1:1000
Cell Signaling Technology HER2 antibody (Cell Signaling, 2248) was used in western blot on human samples at 1:1000. Front Endocrinol (Lausanne) (2014) ncbi
rabbit monoclonal (29D8)
  • WB; human
  • IC; human
In order to study the role of flotillin in the oncogenic effect of ErbB, Cell Signaling Technology HER2 antibody (Cell Signaling, 29D8) was used in western blot on human samples and in immunocytochemistry on human samples. Biochim Biophys Acta (2014) ncbi
rabbit polyclonal
  • WB; human; 1:500
In order to study the ability of miRNA-100 to promote epithelial-to-mesenchymal transition but also to inhibit mammary tumor cell invasiveness and tumorogenesis, Cell Signaling Technology HER2 antibody (Cell signaling Technology, 2242) was used in western blot on human samples at 1:500. PLoS Genet (2014) ncbi
rabbit polyclonal
  • IHC; human; 1:200
In order to study treatment resistance mechanisms in triple-negative breast cancers, Cell Signaling Technology HER2 antibody (Cell Signaling, 2242) was used in immunohistochemistry on human samples at 1:200. Cancer Discov (2014) ncbi
rabbit monoclonal (29D8)
  • WB; human; fig 2
In order to study targeting sEcad for treatment of breast cancer, Cell Signaling Technology HER2 antibody (Cell Signaling, 2165) was used in western blot on human samples (fig 2). Mol Carcinog (2014) ncbi
rabbit monoclonal (29D8)
  • IC; mouse; 1:200
  • WB; mouse; 1:1000
Cell Signaling Technology HER2 antibody (Cell Signaling, 29D8) was used in immunocytochemistry on mouse samples at 1:200 and in western blot on mouse samples at 1:1000. Dev Biol (2013) ncbi
rabbit monoclonal (29D8)
  • IC; human; 1:150
Cell Signaling Technology HER2 antibody (Cell Signaling Technology, 29D8) was used in immunocytochemistry on human samples at 1:150. Breast Cancer Res (2011) ncbi
rabbit polyclonal
  • WB; human
Cell Signaling Technology HER2 antibody (Cell Signaling Technology, 2249) was used in western blot on human samples. Am J Physiol Endocrinol Metab (2011) ncbi
not indicated
  • WB; human
Cell Signaling Technology phospho-ErbB2 (Tyr 1221/1222) phospho-ErbB-2 (Tyr 877) antibodies were used to carry out western blot analysis in order to investigate the cross talk between ErbB2 and PR receptor signaling and the effect on stat3 activation and breast cancer growth.Mol Cell Biol (2009) ncbi
not indicated
  • IHC; human
Cell Signaling rabbit anti-pHER2 antibody was used to perform immunohistochemistry in order to study the function of the fixative in the immunohistochemical detection of phosphoproteins.J Histochem Cytochem (2009) ncbi
not indicated
  • WB; human
Cell Signaling Technology anti-HER2 antibody (1:1000) was used in western blot in order to study the efficacy of lapatinib for preventing the outgrowth of breast cancer cells in the brain in a mouse xenograft model of brain metastasisJ Natl Cancer Inst (2008) ncbi
not indicated
  • WB; human
Cell Signaling Technology anti-phospho HER2 (Tyr1221/1222) antibody (1:1000) was used in western blot in order to study the efficacy of lapatinib for preventing the outgrowth of breast cancer cells in the brain in a mouse xenograft model of brain metastasisJ Natl Cancer Inst (2008) ncbi
not indicated
  • WB; human
Cell Signaling rabbit polyclonal HER2 antibody was used in western blot at 1:1000 dilution in order to demonstrate a functional cross-talk between AR and ErbB2 pathwaysNeoplasia (2008) ncbi
Dako
rabbit polyclonal
  • IHC; human; 1:2000
In order to investigate markers expressed by stromal cells in breast cancer patients, Dako HER2 antibody (DakoCytomation, A0485) was used in immunohistochemistry on human samples at 1:2000. Mol Clin Oncol (2015) ncbi
rabbit polyclonal
  • WB; human
In order to study the mechanism for the metastasis of ErbB2-positive breast cancer cells, Dako HER2 antibody (Dako, A0485) was used in western blot on human samples. J Biol Chem (2015) ncbi
rabbit polyclonal
  • IHC-P; human
In order to identify the effects of the epidermal growth factor receptor 2 and the protein tyrosine kinase 6 in relation to breast cancer treatment, Dako HER2 antibody (DAKO, A0485) was used in immunohistochemistry - paraffin section on human samples. Mol Oncol (2015) ncbi
rabbit polyclonal
  • IHC; human; 1:200
Dako HER2 antibody (Dako, A0485) was used in immunohistochemistry on human samples at 1:200. Tumour Biol (2014) ncbi
rabbit polyclonal
  • IHC; human; 1:200
Dako HER2 antibody (Dako, A0485) was used in immunohistochemistry on human samples at 1:200. Anticancer Res (2014) ncbi
rabbit polyclonal
  • IHC; human
In order to measure protein expression of insulin-like growth factor receptor pathway members and evaluate their prognostic significance across the different early breast cancer subtypes, Dako HER2 antibody (Dako, A0485) was used in immunohistochemistry on human samples. PLoS ONE (2014) ncbi
rabbit polyclonal
  • IHC; human
Dako polyclonal rabbit antihuman c-erbB-2 antibody (Cytomation EnVision A0485 affinity isolated/10 dilution) was used to perform immunohistochemistry in order to investigate the effects of c-erbB-2 expression on endometrial carcinomas.Diagn Pathol (2010) ncbi
not indicated
  • IHC; human
Dako HER2 antibody was used to perform immunohistochemistry in order to clarify that high CENP-F expression was the prognostic indicator of primary breast cancer.BMC Cancer (2008) ncbi
not indicated
  • IHC; human
DAKO monoclonal anti-HER2 antibody was used in immunohistochemistry to identify biomarkers in ductal carcinoma in situ of the breast with microinvasion in paraffin sections from human tumor.BMC Cancer (2008) ncbi
not indicated
  • IHC; human
DAKO anti-HER2 was used to perform immunohistochemistry at 1:400 dilution in order to show that the ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) was identified as a a novel human breast tumour marker.Breast Cancer Res (2008) ncbi
not indicated
  • IHC; human
DAKO rabbit polyclonal anti-HER2 antibody (A0485) was used in immunohistochemistry to study the association of the CD44+/CD24- phenotype to basal-like and BRCA1 hereditary breast cancer in sections from human tumor.Breast Cancer Res (2008) ncbi
not indicated
  • IHC; human
Dako Cytomation rabbit anti-PgR(A0485, 1/800) antibody was used to perform immunohistochemistry in order to study the correlation between the pathologic type of breast cancer and the overexpressed and altered localized atypical protein kinase C lambda/iota.Hum Pathol (2008) ncbi
not indicated
  • IHC; human
Dako rabbit anti-Her2/neu antobody was used in immunohistochemistry at 1:8,000 in order to study the expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancerBreast Cancer Res (2008) ncbi
not indicated
  • IHC; human
DAKO polyclonal HER2 antibody (1:2000) was used in immunohistochemistry in order to investigate the predictive value of clinical and biological markers for a pathological complete remission after a preoperative dose-dense regimen of doxorubicin and docetaxel, with or without tamoxifen, in primary operable breast cancerBreast Cancer Res (2008) ncbi
not indicated
  • IHC; human
Dako rabbit polyclonal anti-HER2 antibody was used to perform immunohistochemistry in order to study the DNA and the protein level of HER1-HER4 in 278 breast cancer patients.Breast Cancer Res (2008) ncbi
not indicated
  • IHC; human
DakoCytomation anti-HER2 antibody (1:1000) was used to perform immunohistochemistry in order to study the expression of CRYAB in breast carcinomas.Ann Diagn Pathol (2008) ncbi
not indicated
  • IHC; human
Dako North America anti-Her2neu antibody (CB11) was used in paraffin sections from human breast cancer and in immunohistochemistry to study the role for IL-6 in driving Stat3 activation in breast cancer.Breast Cancer Res (2007) ncbi
not indicated
  • IHC; human
Dako rabbit polyclonal HER-2/neu antibody was used in immunohistochemistry to study the expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma.Cancer (2005) ncbi
BD Biosciences
mouse monoclonal (3B5)
  • WB; human
  • IC; human; 1:100
BD Biosciences HER2 antibody (BD Transduction, 554299) was used in western blot on human samples and in immunocytochemistry on human samples at 1:100. Clin Exp Metastasis (2015) ncbi
Genentech
not indicated
  • Neut; human
Genentech monoclonal anti-HER2 antibody Herceptin was used as contorl antibody in antibody blocking experiments to investigate the role of PI3k/Akt pathway in macrophage-mediated antibody-dependent cell-mediated cytotoxicity.PLoS ONE (2009) ncbi
not indicated
  • Neut; human
Genentech anti-HER2 murine monoclonal antibody 4D5 and humanized monoclonal antibody trastuzumab (Herceptin) were used in blocking expriments to study gene regulation by anti-HER2 antibodyJ Biol Chem (2005) ncbi
Roche Applied Science
not indicated
  • IHC; human
Ventana anti-HER2 antibody was used to perform immunohistochemistry in order to study the signification of the expression of CD109 in basal-like breast carcinoma.Pathol Int (2008) ncbi
not indicated
  • IHC; human
Ventana Medical Systems rabbit polyclonal anti-HER-2 antibody was used in paraffin sections from human breast cancer and in immunohistochemistry to study the role of 17 estradiol for down-regulation of Cap43/NDRG1/Drg-1 in human breast cancer cells.Clin Cancer Res (2006) ncbi
GE Healthcare Life Biosciences
not indicatedDharmacon ERBB2 siRNA was used for RNAi in order to combine computational simulations, experimental testing of simulation results, and finally reverse engineering of a protein interaction network to define potential therapeutic strategies for de novo trastuzumab resistant breast cancerBMC Syst Biol (2009) ncbi
Leica Biosystems
  • IHC; human
Novocastra anti-c-erbB-2 monoclonal antibody was used to perform immunohistochemistry in order to study the correlation of EGF and EGFR with metastasis of pancreatic ductal carcinoma.Anticancer Res (2008) ncbi
not indicated
  • IHC; human
NovoCastra anti-HER2/neu antibody CB11 was used in immunohistochemistry to study the association of alpha-Methylacyl-CoA racemase protein expression with the degree of differentiation in breast cancer.Cancer Epidemiol Biomarkers Prev (2005) ncbi
others
not indicated
  • IHC; human
Carpinteria monoclonal Her-2/neu antibody was used in immunohistochemistry in order to evaluate the expression of EGFR in a series of 16 gallbladder cancer patients from North AmericaInt J Med Sci (2008) ncbi
Articles Reviewed
  1. Jonathan D Black et al. (2015). "PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas".PMID 26325104
  2. Nilgun Kapucuoglu et al. (2015). "The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer".PMID 26298632
  3. Jean McBryan et al. (2015). "Transcriptomic Profiling of Sequential Tumors from Breast Cancer Patients Provides a Global View of Metastatic Expression Changes Following Endocrine Therapy".PMID 26240272
  4. Maik Dahlhoff et al. (2015). "ERBB3 is required for tumor promotion in a mouse model of skin carcinogenesis".PMID 26194695
  5. Fiorita Gonzales Lopes Mundim et al. (2015). "MYC is expressed in the stromal and epithelial cells of primary breast carcinoma and paired nodal metastases".PMID 26137258
  6. Ha Nul Yu et al. (2015). "Neuregulin 1 Controls Glutamate Uptake by Up-regulating Excitatory Amino Acid Carrier 1 (EAAC1)".PMID 26092725
  7. Lu Yang et al. (2015). "Inhibition of ERBB2-overexpressing Tumors by Recombinant Human Prolidase and Its Enzymatically Inactive Mutant".PMID 26086037
  8. Valerie Cui Yun Koh et al. (2015). "Characteristics and behaviour of screen-detected ductal carcinoma in situ of the breast: comparison with symptomatic patients".PMID 26077641
  9. Björn Koos et al. (2015). "Proximity-dependent initiation of hybridization chain reaction".PMID 26065580
  10. Giulia Ronchi et al. (2016). "The Neuregulin1/ErbB system is selectively regulated during peripheral nerve degeneration and regeneration".PMID 26061116
  11. K J Kurppa et al. (2016). "Activating ERBB4 mutations in non-small cell lung cancer".PMID 26050618
  12. Wolfgang Jäger et al. (2015). "Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies".PMID 26041878
  13. Bianca T Hofmann et al. (2015). "COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer".PMID 26021314
  14. Rafael de Deus Moura et al. (2015). "Breast cancer in very young women: Clinicopathological study of 149 patients ≤25 years old".PMID 25998784
  15. Elizabeth G Demicco et al. (2015). "Histologic variability in solitary fibrous tumors reflects angiogenic and growth factor signaling pathway alterations".PMID 25976141
  16. C C Nwafor et al. (2015). "Pattern of hormone receptors and human epidermal growth factor receptor 2 status in sub-Saharan breast cancer cases: Private practice experience".PMID 25966732
  17. Nesrin Ugras et al. (2014). "Relationship between HER-2, COX-2, p53 and clinicopathologic features in gastric adenocarcinoma. Do these biomarkers have any prognostic significance?".PMID 25910300
  18. Weihong Ding et al. (2015). "Human epidermal growth factor receptor 2: a significant indicator for predicting progression in non-muscle-invasive bladder cancer especially in high-risk groups".PMID 25894367
  19. Denise A Yardley et al. (2015). "Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival".PMID 25886996
  20. Callie R Merry et al. (2015). "Integrative transcriptome-wide analyses reveal critical HER2-regulated mRNAs and lincRNAs in HER2+ breast cancer".PMID 25749757
  21. Ozge Gumusay et al. (2015). "Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites".PMID 25732909
  22. Raju R Rayavarapu et al. (2015). "The role of multicellular aggregation in the survival of ErbB2-positive breast cancer cells during extracellular matrix detachment".PMID 25681438
  23. Ming Liang Oon et al. (2015). "Cancer stem cell and epithelial-mesenchymal transition markers predict worse outcome in metaplastic carcinoma of the breast".PMID 25677743
  24. F Darío Cuello-Carrión et al. (2015). "HER2 and β-catenin protein location: importance in the prognosis of breast cancer patients and their correlation when breast cancer cells suffer stressful situations".PMID 25636904
  25. Jung Yoon Yoo et al. (2015). "Role of Mig-6 in hepatic glucose metabolism".PMID 25594850
  26. Vassilis Papanikolaou et al. (2015). "Synergy of leptin/STAT3 with HER2 receptor induces tamoxifen resistance in breast cancer cells through regulation of apoptosis-related genes".PMID 25539992
  27. Jing Liu et al. (2015). "Clinicopathologic characteristics and prognosis of primary squamous cell carcinoma of the breast".PMID 25476498
  28. Jinhua Tu et al. (2015). "Significance of human epidermal growth factor receptor 2 expression in colorectal cancer".PMID 25452770
  29. Lawrence A Scheving et al. (2015). "Loss of hepatocyte EGFR has no effect alone but exacerbates carbon tetrachloride-induced liver injury and impairs regeneration in hepatocyte Met-deficient mice".PMID 25414100
  30. Yong Sang Hong et al. (2014). "Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models".PMID 25350844
  31. Marie Claude Perry et al. (2014). "ERBB2 deficiency alters an E2F-1-dependent adaptive stress response and leads to cardiac dysfunction".PMID 25246633
  32. Natalie Falkenberg et al. (2015). "Additive impact of HER2-/PTK6-RNAi on interactions with HER3 or IGF-1R leads to reduced breast cancer progression in vivo".PMID 25241146
  33. Filomena M Carvalho et al. (2014). "Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil".PMID 25174527
  34. Kiran Mahajan et al. (2014). "ACK1 tyrosine kinase interacts with histone demethylase KDM3A to regulate the mammary tumor oncogene HOXA1".PMID 25148682
  35. Erica L Carpenter et al. (2014). "Dielectrophoretic capture and genetic analysis of single neuroblastoma tumor cells".PMID 25133137
  36. Qinchuan Wang et al. (2014). "Lin28 promotes Her2 expression and Lin28/Her2 predicts poorer survival in gastric cancer".PMID 25128063
  37. Yongjun Cha et al. (2014). "Immunohistochemical features associated with sensitivity to lapatinib-plus-capecitabine and resistance to trastuzumab in HER2-positive breast cancer".PMID 25075058
  38. Curtis H Kugel et al. (2014). "Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor".PMID 25035390
  39. Yangyang Wang et al. (2014). "Blocking the formation of radiation-induced breast cancer stem cells".PMID 25003837
  40. J Wang et al. (2015). "Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells".PMID 24909170
  41. Li Zeng et al. (2014). "Effects of physiological levels of the green tea extract epigallocatechin-3-gallate on breast cancer cells".PMID 24847310
  42. Samil Jung et al. (2014). "Distinct regulatory effect of the p34SEI-1 oncoprotein on cancer metastasis in HER2/neu-positive and -negative cells".PMID 24789658
  43. Nagham Asp et al. (2014). "Flotillin depletion affects ErbB protein levels in different human breast cancer cells".PMID 24747692
  44. Keshuo Ding et al. (2014). "Artemin, a member of the glial cell line-derived neurotrophic factor family of ligands, is HER2-regulated and mediates acquired trastuzumab resistance by promoting cancer stem cell-like behavior in mammary carcinoma cells".PMID 24737320
  45. Shahin Assefnia et al. (2014). "Trp63 is regulated by STAT5 in mammary tissue and subject to differentiation in cancer".PMID 24692510
  46. Emilie Balk-Møller et al. (2014). "A marker of endocrine receptor-positive cells, CEACAM6, is shared by two major classes of breast cancer: luminal and HER2-enriched".PMID 24655379
  47. Giannis Mountzios et al. (2014). "Differential expression of the insulin-like growth factor receptor among early breast cancer subtypes".PMID 24637962
  48. Dahu Chen et al. (2014). "miR-100 induces epithelial-mesenchymal transition but suppresses tumorigenesis, migration and invasion".PMID 24586203
  49. John A Jakob et al. (2015). "Phase II study of gefitinib in patients with advanced salivary gland cancers".PMID 24585506
  50. Alizée Boin et al. (2014). "Proteomic screening identifies a YAP-driven signaling network linked to tumor cell proliferation in human schwannomas".PMID 24558021
  51. Justin M Balko et al. (2014). "Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets".PMID 24356096
  52. Chengshan Xu et al. (2014). "S100A14, a member of the EF-hand calcium-binding proteins, is overexpressed in breast cancer and acts as a modulator of HER2 signaling".PMID 24285542
  53. Jesús G Silva et al. (2013). "Expression of c-erbB-2 in breast cancer cell lines as experimental receptor of magnetic nanoparticles".PMID 24110733
  54. James J Sollome et al. (2014). "HER2/HER3 regulates extracellular acidification and cell migration through MTK1 (MEKK4)".PMID 24036211
  55. Malwina Mencel et al. (2013). "Neuregulin upregulates microglial α7 nicotinic acetylcholine receptor expression in immortalized cell lines: implications for regulating neuroinflammation".PMID 23936190
  56. Jie Ren et al. (2013). "MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency".PMID 23860775
  57. Jing Zhang et al. (2013). "An associated classification of triple negative breast cancer: the risk of relapse and the response to chemotherapy".PMID 23826420
  58. Sabine M Brouxhon et al. (2014). "Soluble-E-cadherin activates HER and IAP family members in HER2+ and TNBC human breast cancers".PMID 23776059
  59. Jie Han et al. (2013). "Interaction between Her2 and Beclin-1 proteins underlies a new mechanism of reciprocal regulation".PMID 23703612
  60. Malgorzata Magdalena Sak et al. (2013). "Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3".PMID 23698633
  61. Yang Zhao et al. (2014). "Primary acinic cell carcinoma of the breast: a case report and review of the literature".PMID 23564703
  62. Cynthia Brito Lins Pereira et al. (2013). "Prognostic and predictive significance of MYC and KRAS alterations in breast cancer from women treated with neoadjuvant chemotherapy".PMID 23555992
  63. Cristina Harmelink et al. (2013). "Myocardial Mycn is essential for mouse ventricular wall morphogenesis".PMID 23063798
  64. Cristina Cadenas et al. (2012). "Glycerophospholipid profile in oncogene-induced senescence".PMID 22178194
  65. Karolina Lindberg et al. (2011). "Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity".PMID 21492444
  66. Fu Ning Hsu et al. (2011). "The significance of Her2 on androgen receptor protein stability in the transition of androgen requirement in prostate cancer cells".PMID 21364123
  67. Aylin Ege Gul et al. (2010). "The relationship of cerb B 2 expression with estrogen receptor and progesterone receptor and prognostic parameters in endometrial carcinomas".PMID 20167054
  68. Juxiang Cao et al. (2009). "Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity".PMID 19369943
  69. Wei Zhou et al. (2009). "EMP3 overexpression in primary breast carcinomas is not associated with epigenetic aberrations".PMID 19270820
  70. Trupti Joshi et al. (2009). "The PtdIns 3-kinase/Akt pathway regulates macrophage-mediated ADCC against B cell lymphoma".PMID 19148288
  71. Ozgur Sahin et al. (2009). "Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance".PMID 19118495
  72. Cecilia J Proietti et al. (2009). "Activation of Stat3 by heregulin/ErbB-2 through the co-option of progesterone receptor signaling drives breast cancer growth".PMID 19103753
  73. Shigeto Ueda et al. (2008). "Expression of centromere protein F (CENP-F) associated with higher FDG uptake on PET/CT, detected by cDNA microarray, predicts high-risk patients with primary breast cancer".PMID 19102762
  74. Janine A Burns et al. (2009). "Choice of fixative is crucial to successful immunohistochemical detection of phosphoproteins in paraffin-embedded tumor tissues".PMID 19001637
  75. J Wen et al. (2009). "Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions".PMID 18997820
  76. J R Smith et al. (2009). "Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors".PMID 18931700
  77. Yasuhiro Okumura et al. (2008). "Identification of biomarkers in ductal carcinoma in situ of the breast with microinvasion".PMID 18837981
  78. Matthew Kaufman et al. (2008). "EGFR expression in gallbladder carcinoma in North America".PMID 18825277
  79. Brunilde Gril et al. (2008). "Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain".PMID 18664652
  80. Nuran Bektas et al. (2008). "The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer".PMID 18627608
  81. Gabriella Honeth et al. (2008). "The CD44+/CD24- phenotype is enriched in basal-like breast tumors".PMID 18559090
  82. Yasuyuki Kojima et al. (2008). "The overexpression and altered localization of the atypical protein kinase C lambda/iota in breast cancer correlates with the pathologic type of these tumors".PMID 18538170
  83. Christina Magkou et al. (2008). "Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas".PMID 18522728
  84. Ali Naderi et al. (2008). "A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer".PMID 18516291
  85. Anna Pryczynicz et al. (2008). "Expression of EGF and EGFR strongly correlates with metastasis of pancreatic ductal carcinoma".PMID 18505086
  86. Yasmine Nadler et al. (2008). "Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer".PMID 18430249
  87. Masaki Hasegawa et al. (2008). "CD109 expression in basal-like breast carcinoma".PMID 18429827
  88. Michiyo Yamada et al. (2008). "Amphiregulin is a promising prognostic marker for liver metastases of colorectal cancer".PMID 18413824
  89. Gunter von Minckwitz et al. (2008). "Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast".PMID 18380893
  90. Andrea Sassen et al. (2008). "Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients".PMID 18182100
  91. Stephanie M Sitterding et al. (2008). "AlphaB-crystallin: a novel marker of invasive basal-like and metaplastic breast carcinomas".PMID 18164413
  92. Josie Ursini-Siegel et al. (2007). "Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor development".PMID 17636013
  93. Marjan Berishaj et al. (2007). "Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer".PMID 17531096
  94. David L Shattuck et al. (2007). "LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy".PMID 17178829
  95. Lily Yen et al. (2006). "Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth".PMID 17145873
  96. Abbas Fotovati et al. (2006). "17Beta-estradiol induces down-regulation of Cap43/NDRG1/Drg-1, a putative differentiation-related and metastasis suppressor gene, in human breast cancer cells".PMID 16707596
  97. Mei Sun et al. (2005). "Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease".PMID 16018990
  98. Agnieszka K Witkiewicz et al. (2005). "Alpha-methylacyl-CoA racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysis".PMID 15941950
  99. Hu Xu et al. (2005). "Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells".PMID 15767552
  100. Scott K Kuwada et al. (2005). "Integrin alpha5/beta1 expression mediates HER-2 down-regulation in colon cancer cells".PMID 15757908
  101. Laundette P Jones et al. (2005). "Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer".PMID 15750629
  102. Dafydd G Thomas et al. (2005). "Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma".PMID 15641030
  103. Xiao Feng Le et al. (2005). "Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling".PMID 15504738
  104. Wai Kuen Ng et al. (2002). "Fine-needle aspiration cytology findings of an uncommon micropapillary variant of pure mucinous carcinoma of the breast: review of patients over an 8-year period".PMID 12378595
  105. I Noci et al. (2001). "Longstanding survival without cancer progression in a patient affected by endometrial carcinoma treated primarily with leuprolide".PMID 11487260